File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/pr8080937
- Scopus: eid_2-s2.0-85089224335
- WOS: WOS:000564779200001
Supplementary
- Citations:
- Appears in Collections:
Article: The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19
Title | The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19 |
---|---|
Authors | |
Keywords | SARS-CoV coronavirus traditional Chinese medicine COVID-19 natural products |
Issue Date | 2020 |
Publisher | MDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/processes |
Citation | Processes, 2020, v. 8 n. 8, p. article no. 937 How to Cite? |
Abstract | Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there have been more than 10 million reported cases, more than 517,000 deaths in 215 countries, areas or territories. There is no effective antiviral medicine to prevent or treat COVID-19. Natural products and traditional medicine products with known safety profiles are a promising source for the discovery of new drug leads. There is increasing number of publications reporting the effect of natural products and traditional medicine products on COVID-19. In our review, we provide an overview of natural products and their derivatives or mimics, as well as traditional medicine products, which were reported to exhibit potential to inhibit SARS-CoV-2 infection in vitro, and to manage COVID-19 in vivo, or in clinical reports or trials. These natural products and traditional medicine products are categorized in several classes: (1) anti-malaria drugs including chloroquine and hydroxychloroquine, (2) antivirals including nucleoside analogs (remdesivir, favipiravir, β-D-N4-hydroxycytidine, ribavirin and among others), lopinavir/ritonavir and arbidol, (3) antibiotics including azithromycin, ivermectin and teicoplanin, (4) anti-protozoal drug, emetine, anti-cancer drug, homoharringtonine, and others, as well as (5) traditional medicine (Lian Hua Qing Wen Capsule, Shuang Huang Lian Oral Liquid, Qingfei Paidu Decoction and Scutellariae Radix). Randomized, double-blind and placebo-controlled large clinical trials are needed to provide solid evidence for the potential effective treatment. Currently, drug repurposing is a promising strategy to quickly find an effective treatment for COVID-19. In addition, carefully combined cocktails need to be examined for preventing a COVID-19 pandemic and the resulting global health concerns. |
Persistent Identifier | http://hdl.handle.net/10722/284785 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, D | - |
dc.contributor.author | Huang, J | - |
dc.contributor.author | Yeung, AWK | - |
dc.contributor.author | Tzvetkov, NT | - |
dc.contributor.author | Horbańczuk, JO | - |
dc.contributor.author | Willschke, H | - |
dc.contributor.author | Gai, Z | - |
dc.contributor.author | Atanasov, AG | - |
dc.date.accessioned | 2020-08-07T09:02:36Z | - |
dc.date.available | 2020-08-07T09:02:36Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Processes, 2020, v. 8 n. 8, p. article no. 937 | - |
dc.identifier.uri | http://hdl.handle.net/10722/284785 | - |
dc.description.abstract | Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there have been more than 10 million reported cases, more than 517,000 deaths in 215 countries, areas or territories. There is no effective antiviral medicine to prevent or treat COVID-19. Natural products and traditional medicine products with known safety profiles are a promising source for the discovery of new drug leads. There is increasing number of publications reporting the effect of natural products and traditional medicine products on COVID-19. In our review, we provide an overview of natural products and their derivatives or mimics, as well as traditional medicine products, which were reported to exhibit potential to inhibit SARS-CoV-2 infection in vitro, and to manage COVID-19 in vivo, or in clinical reports or trials. These natural products and traditional medicine products are categorized in several classes: (1) anti-malaria drugs including chloroquine and hydroxychloroquine, (2) antivirals including nucleoside analogs (remdesivir, favipiravir, β-D-N4-hydroxycytidine, ribavirin and among others), lopinavir/ritonavir and arbidol, (3) antibiotics including azithromycin, ivermectin and teicoplanin, (4) anti-protozoal drug, emetine, anti-cancer drug, homoharringtonine, and others, as well as (5) traditional medicine (Lian Hua Qing Wen Capsule, Shuang Huang Lian Oral Liquid, Qingfei Paidu Decoction and Scutellariae Radix). Randomized, double-blind and placebo-controlled large clinical trials are needed to provide solid evidence for the potential effective treatment. Currently, drug repurposing is a promising strategy to quickly find an effective treatment for COVID-19. In addition, carefully combined cocktails need to be examined for preventing a COVID-19 pandemic and the resulting global health concerns. | - |
dc.language | eng | - |
dc.publisher | MDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/processes | - |
dc.relation.ispartof | Processes | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | SARS-CoV | - |
dc.subject | coronavirus | - |
dc.subject | traditional Chinese medicine | - |
dc.subject | COVID-19 | - |
dc.subject | natural products | - |
dc.title | The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19 | - |
dc.type | Article | - |
dc.identifier.email | Yeung, AWK: ndyeung@hku.hk | - |
dc.identifier.authority | Yeung, AWK=rp02143 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/pr8080937 | - |
dc.identifier.scopus | eid_2-s2.0-85089224335 | - |
dc.identifier.hkuros | 312514 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | article no. 937 | - |
dc.identifier.epage | article no. 937 | - |
dc.identifier.eissn | 2227-9717 | - |
dc.identifier.isi | WOS:000564779200001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 2227-9717 | - |